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Neurogenesis and gliogenesis modulation in 
cerebral ischemia by CDK5 RNAi-based therapy
Juan Ignacio Muñoz-Manco, Johanna Andrea Gutiérrez-Vargas, Gloria Patricia Cardona-Gómez
Grupo de Neurociencias de Antioquia, Área de Neurobiología Celular y Molecular, 
Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
Introduction: Cerebral ischemia is the third cause of death risk in Colombia and the first cause of 
physical disability worldwide. Different studies on the silencing of the cyclin-dependent kinase 5 (CDK5) 
have shown that reducing its activity is beneficial in ischemic contexts. However, its effect on neural cell 
production after cerebral ischemia has not been well studied yet. 
Objective: To evaluate CDK5 silencing on the production of neurons and astrocytes after a focal 
cerebral ischemia in rats.
Materials and methods: We used 40 eight-week-old male Wistar rats. Both sham and ischemia 
groups were transduced at CA1 hippocampal region with an adeno-associated viral vector using a non-
interfering (shSCRmiR) and an interfering sequence for CDK5 (shCDK5miR). We injected 50 mg/kg of 
bromodeoxyuridine intraperitoneally from hour 24 to day 7 post-ischemia. We assessed the neurological 
abilities during the next 15 days and we measured the immunoreactivity of bromodeoxyuridine (BrdU), 
doublecortin (DCX), NeuN, and glial fibrillary acid protein (GFAP) from day 15 to day 30 post-ischemia. 
Results: Our findings showed that CDK5miR-treated ischemic animals improved their neurological 
score and presented increased BrdU+ cells 15 days after ischemia, which correlated with higher DCX 
and lower GFAP fluorescence intensities, and, although mature neurons populations did not change, 
GFAP immunoreactivity was still significantly reduced at 30 days post-ischemia in comparison with 
untreated ischemic groups. 
Conclusion: CDK5miR therapy generated the neurological recovery of ischemic rats associated with 
the induction of immature neurons proliferation and the reduction of GFAP reactivity at short and long-
term post-ischemia.
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Modulación de la neurogénesis y la gliogénesis en la isquemia cerebral mediante una terapia 
basada en la interferencia de CDK5
Introducción. La isquemia cerebral es la tercera causa de riesgo de muerte en Colombia y la primera 
causa de discapacidad física en el mundo. En diversos estudios en los que se silenció la cinasa 5 
dependiente de la ciclina (CDK5) se ha demostrado que la reducción de su actividad es beneficiosa 
frente a la isquemia. Sin embargo, su efecto sobre la neurogénesis después de la isquemia no se ha 
dilucidado suficientemente.
Objetivo. Evaluar el silenciamiento de la CDK5 en la neurogénesis y la gliogénesis después de la 
isquemia cerebral focal en ratas.
Materiales y métodos. Se usaron 40 machos de rata Wistar de ocho semanas de edad. Los grupos 
de control y los isquémicos sometidos a transducción en la región del hipocampo CA1, se inyectaron 
intraperitonealmente por estereotaxia con 50 mg/kg de bromodesoxiuridina (BrdU) a partir de las 24 
horas y hasta el día 7 después de la isquemia, con un vector viral asociado a adenovirus usando 
una secuencia no interferente (SCRmiR) y una interferente (CDK5miR). Se evaluó la capacidad 
neurológica durante los quince días siguientes y se detectó la capacidad de inmunorreacción para la 
BrdU, la proteína doblecortina (DCX), los núcleos neuronales (NeuN), y la proteína fibrilar acídica de 
la glía (Glial Fibrillary Acidic Protein, GFAP) a los 15 y 30 días de la isquemia.
Resultados. Los animales isquémicos tratados con CDK5miR mejoraron su puntuación neurológica 
y presentaron un incremento de la BrdU+ a los 15 días de la isquemia, lo cual se correlacionó con 
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una mayor intensidad de la DCX+ y una menor de la GFAP+. No hubo modificación de los NeuN+, 
pero sí una reducción significativa de la GFAP+ a los 30 días de la isquemia en los animales tratados 
comparados con los animales isquémicos no tratados.
Conclusión. La terapia con CDK5miR generó la recuperación neurológica de ratas isquémicas 
asociada con la inducción de la neurogénesis y el control de la capacidad de reacción de la proteína 
GFAP a corto y largo plazo después de la isquemia.
Palabras clave: isquemia encefálica; neurogénesis, cinasa 5 dependiente de la ciclina.
doi: https://doi.org/10.7705/biomedica.v38i4.3800
Cerebrovascular disease (CVD) represents a crit-
ical public health problem and it is considered 
the first cause of mental and physical disabilities 
around the world (1,2). Ischemic stroke is a 
CVD, which mainly generates a focal ischemia 
by the occlusion of the middle cerebral artery 
characterized by a core and a penumbra zone 
(3). In the ischemic core, cellular necrotic events 
occur that make it impossible to rescue cells after 
the insult; however, the apoptotic cell death caused 
by nutrient deprivation, the oxidative stress, and 
the excitotoxicity occurring in the penumbra zone 
represent a key target for therapeutic intervention 
in cerebral ischemia (4,5).
During cerebral infarction, various affected molec-
ular actors are involved in neurotransmission, cell 
adhesion, and cytoskeletal remodelling, among 
others (6). CDK5 is a cyclin dependent kinase 
implied in neurodevelopment and neurotransmis-
sion, but its over-activation is associated with 
degeneration. Given that an increased cleavage 
of p35 (activator) to p25 generates an abnormal 
production of the CDK5/p25 complex with a 
sustained activation of the enzyme, an unbalancing 
phosphorylation of tau and of several substrates 
related to the loss of plasticity and neurovascular 
unit, as well as dementia (6-9), it has been 
suggested that the prevention of a sustained 
activity of CDK5 is neuroprotective (10-12). 
In this context, it is necessary to gain a deeper 
understanding of CDK5 RNAi-based therapy for 
future translational studies in humans, which are in 
great clinical demand and have a significant social 
impact (13). In this study, we analyzed the role of 
CDK5miR on neurogenesis and gliogenesis after 
an ischemic stroke.
Materials and methods
Animal model 
Procedures in animals were performed according 
to the ARRIVE guidelines, the “Guide for the 
care and use of laboratory animals”, 8th edition, 
published by the National Institutes of Health 
(NIH), and the Colombian standards (Law 84/1989 
and Resolution 8430/1993), taking special care to 
minimize suffering and reduce their number. The 
study was approved by the Ethics Committee 
for Animal Experimentation of the University of 
Antioquia, Medellín, Colombia.
Animals were obtained from a specific pathogen-free 
colony of the vivarium at the Sede de Investigación 
Universitaria (SIU), University of Antioquia, Medellín, 
Colombia. Rats were maintained in groups of five 
with food and water ad libitum and on a 12:12-hour 
dark:light cycle. We used 40 eight-week-old male 
Wistar rats (Rattus novergicus albinus) of average 
size and an average weight of 350 g. Ten rats per 
experimental group were used for neurological 
scoring. In addition, we used 5 per experimental 
group for the histologic assessments.
Surgical procedure
We performed a transient middle cerebral artery 
occlusion (t-MCAO) and reperfusion as described 
previously (12,14). Initially, animals were anaesthe-
tized with a mixture of ketamine via IP (60 mg/kg; 
Holliday Scott S.A. Int. Neyer, Buenos Aires, Argen-
tina), xylazine (5 mg/kg; Synthesis Ltda. & Cia., 
S.C.A, Bogotá, Colombia), subcutaneous atropine 
(100 mg/kg; Erma S.A., Bogotá, Colombia); they 
also received an inhalational mixture of 2% to 4% 
of isoflurane (Baxter, Deerfield, IL, USA) and 96% 
oxygen using an inhalation anaesthesia machine 
(VMC™ Table top gas anaesthesia Instrument). 
The right common carotid artery (CCA) was exposed 
and carefully isolated from the vagus nerve (VN); 
the right external and internal carotid arteries (ECA 
and ICA) were exposed and isolated. ECA ascend-
ing pharyngeal artery, superior thyroid and occipital 
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branches were cauterized by electrocoagulation 
(AARON Bipolar Cautery™, Albany, NY, USA). 
The ICA artery pterygopalatine first branch was 
isolated. The distal portion of the ECA was tied with 
a 6/0 nylon and then cut. A 4-0 monofilament nylon 
(Corpaul, Bogotá, Colombia), previously rounded 
at one end by flaming and coated with poly-L-lysine 
solution (0.1% w/v in deionized water; Sigma, St 
Louis, MO, USA), and inserted 17-19 mm from the 
ECA to the ICA to occlude the MCA and its origin. 
Then, we verified that the monofilament was not 
inside the pterygopalatine artery. The incision was 
sutured leaving a bulge of 1 cm. After 60 minutes, 
the nylon was removed allowing reperfusion and 
the wound was closed.
Sham animals were subjected to the same proce-
dures, but the filament was not introduced. Half of 
the animals were euthanized 15 days after reperfu-
sion and the other half, 30 days after for which all 
animals were anesthetized with xylazine 10 mg/kg 
+ ketamine 90 mg/kg and immediately perfused 
with 4% paraformaldehyde (0.1 M phosphate buffer 
[PBS], pH 7.4). Brains were carefully removed and 
post-fixed with 4% paraformaldehyde at 4°C for 
48 hours, then preserved by a sucrose gradient 
(7%, 25%, 30%) at 4°C; they were then placed 
in a cryopreservation solution at -20°C. Coronal 
sections were sectioned at 50 μm with a vibrating 
blade microtome (VT1000S™, Leica Microsystems, 
Nussloch, Germany).
Short hairpin RNAmiR delivery
During the t-MCA occlusion, at 30 minutes, we 
performed a right hippocampal stereotaxic injection 
with anteroposterior (AP) coordinates of -2.56 mm, 
mediolateral (ML) 0.8 mm and dorsoventral (DV) 4.1 
mm. We used a 10 μL Hamilton syringe for injection 
at a rate of 0.2 μL/min of a solution containing 
adeno-associated viral (AAV) particles obtained 
from the Davidson Laboratory (University of 
Iowa Viral Vector Core) with the RNAi sequences 
for silencing CDK5 (short hairpin CDK5miR) and 
a control scrambled RNA sequence (shSCRmiR) 
(12,15-18) for treating ischemic and control ani-
mals, respectively. Five minutes elapsed after the 
infusion before withdrawing the syringe. We injected 
a volume of 2.5 μl of AAV2.5.shSCRmiR.GFP or 
AAV2.5.shCDK5miR.GFP as previously described 
(12,18). After the injection, we proceeded to suture 
the animals keeping them in observation until their 
awakening (figure 1 A,B).
Figure 1. Neurological recovery induced by CDK5 silencing in ischemic rats. A) Experimental design to evaluate the effect of 
CDK5 RNAi on neural population and neurological performance after an ischemic insult. B) Ipsilateral injection site at stereotaxic 
coordinates AP -2.56, ML 0.8, and DV 4.1. and evaluated hippocampal regions (g: granular; sg: subgranular; p: polimorphic zone. C) 
Neurological analysis of CDK5 silencing in ischemic rats. The error bars indicate the SEM. All data are presented as mean ± SEM. 
Sham-SCR: Control group treated with shSCRmiR; Sham-CDK5: Control group treated with shCDK5miR; Isch-SCR: Ischemic group 
treated with SCRmiR; Isch- CDK5: Ischemic group treated with shCDK5miR. n=10, p<0.05 = *; p<0.001 = **.
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Recovery and neurological evaluation
Animals were evaluated from day 1 to 15 after 
the t-MCAO (N=10). Neurological evaluation was 
scored on an 18-point scale. The evaluation was 
divided into six independent tests scored from 0 to 
3 to determine the following parameters: 
1) Cage exploration and spontaneous activity;
2) symmetry in limb movement;
3) forepaw outstretching; 
4) climbing; 
5) body proprioception, and 
6) response to vibrissae touch (12,18,19) (figure 1A). 
The highest possible score in the tests was 18, 
which indicated there were no neurological defi-
cits, while the lowest was 3 for the most severe 
impairment. Neurological evaluation was performed 
every day and in the same order in all animals. To 
validate and reduce bias, a double-blind procedure 
was performed recording videos for every animal 
during the test. 
Insertion of 5-Bromo-2-deuxyuridine
For the BrdU (Catalog Number B5002, Sigma-
Aldrich) insertion, we injected rats via IP twice a 
day during seven days after ischemia at 50 mg/kg 
(0.1 M phosphate buffer [PBS], pH 7.4).
Immunohistochemistry
Brain sections were treated with methanol and 
hydrogen peroxide (H2O2) in 0.1M PBS (pH 7.4) 
to inhibit endogenous peroxidase activity for 20 
minutes while free-floating with moderate shaking. 
Subsequently, we washed them three times with 
0.3% (v/v) Triton X-100™ (Sigma-Aldrich) in 0.1 
M PBS to increase tissue permeability and we 
then incubated for 30 minutes with Triton™ 0.5% 
(v / v) X-100 in 0.1 M PBS. Then, we backwashed 
with 0.3% (v/v) Triton X-100™ in 0.1 M PBS for 
three times.
For BrdU, we denaturalized brain DNA sections with 
HCl 2N for 20 minutes at 37°C, we washed three 
times with 0.3% (v/v) Triton X-100™ in 0.1 M PBS, 
then incubated with citrate buffer (Sodium citrate 
10Mm, 0.05% tween 20, pH 6.0) for 10 minutes at 
room temperature and, finally, we washed three 
times with 0.3% (v/v) TritonX-100™ in 0.1 M PBS. 
Nonspecific binding sites were blocked by pre-
incubation with BSA (1%) and 0.3% (v/v) Triton 
X-100™ in 0.1 M PBS for 1 hour. 
Sections were incubated 24 hours while free-
floating with moderate shaking and with the pri-
mary anti-body diluted in incubation solution (0.1 M 
PBS with 0.3% (v/v) Triton X-100™ and 0.3% BSA) 
at 4°C. 
Anti-BrdU (1:100 mouse monoclonal B8434, Sigma-
Aldrich) was used to detect bromodeoxyuridine 
(BrdU) specifically incorporated into the DNA. 
Next day, sections were washed 5 minutes with 
0.1 M PBS three times and incubated with the 
secondary antibody (1:250 biotinylated mouse, 
Pierce) for 1 hour at room temperature and then 
washed 3 times with 0.1 M PBS, incubated with 
Avidin-Biotin complex (Pierce complex™; 1: 250 
reagents A and B), and washed again three more 
times and developed with a chromogenic reac-
tion diaminobenzidine (DBA) in 0.01% H2O2. For 
negative controls, we followed the same protocol 
for each experimental group without incubation 
with the respective primary antibody.
Sections were mounted on glass slides, dehydrated 
with increasing concentration of alcohol (70%, 96%, 
100%) and cleared with xylene. Finally, the slides 
were sealed using Vecta-shield mounting medium 
(Vector Laboratories, Burlingame, CA, USA), and 
then analyzed through a light microscope (Nikon 
Eclipse E200™). Images were captured using a 
Nikon digital camera (Sight DS-L1™). Quantifica-
tion of immunoreactivity in the hippocampus was 
determined using a 10X objective. Photomicro-
graphs were analyzed using the ImageJ software 
program (version 1.45, US National Institutes of 
Health, Bethesda, MD, USA). To quantify the rela-
tive intensity of immunostaining, we modified the 
images to a binary system and obtained integrated 
densities (relative units) substracting automatically 
the background for each image.
Immunofluorescence 
Brain slices were initially heated (80°C) in 10mM 
Tris pH 6.0 to increase exposure of the antigen 
and then treated with ammonium chloride (NH4Cl) 
for 20 minutes to avoid autofluorescence. Three 
washes with 0.3% v/v Triton X-100™ in 0.1M 
PBS were made to increase tissue permeability. 
For BrdU, we denaturalized DNA brain sections 
with HCl 2N for 20 minutes at 37°C, washed them 
three times with 0.3% (v/v) Triton X-100™ in 0.1 M 
PBS, and then incubated them with citrate buffer 
(sodium citrate 10 Mm, 0.05% tween 20, pH 6.0) 
for 10 minutes at room temperature to finally wash 
them three times with 0.3% (v/v) Triton X-100™ in 
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0.1 M PBS. Nonspecific binding sites were blocked 
by preincubation with BSA (3%) and 0.5% (v/v) 
Triton X-100™ in 0.1 M PBS for 1 hour. 
Sections were incubated overnight while free-
floating with moderate shaking at 4°C with the 
respective primary anti-BrdU (mouse monoclonal 
1: 100, Sigma) for the new cells produced, anti-
DCX (polyclonal rabbit 1: 250, Abcam) for immature 
neurons, anti-GFAP (rabbit polyclonal 1: 500, 
Sigma) for astrocytic cells and anti-NeuN (polyclonal 
rabbit 1: 500, Millipore) for mature neuronal cells. 
After three washes, tissues were incubated with 
secondary antibodies: Rabbit Alexa Fluor 594™, 
and mouse Alexa Fluor 350™ (molecular probes, 
1:1,000) for 90 minutes at room temperature. Finally, 
we washed with PBS and slides were coverslipped 
using Gel Mount™ (BioMeda, Hatfield, PA, USA) in 
dark conditions. For negative controls, we followed 
the same protocol for each experimental group 
without incubation with the respective primary 
antibodies. Tissues were observed with a motorized 
spinning disk confocal microscope (Disk Scan Unit) 
Olympus IX 81™ (Olympus, Latin America, Inc., 
Miami, FL, USA). Images were photographed at 
10X and the analysis was performed by evaluating 
the fluorescence intensity (FI) using the Image Pro 
Plus (Media Cybernetics) software.
Statistical analysis
For the neurological analysis, we used ten 
(10) animals per group and for the histological 
analysis, five (5) per group. The data obtained 
from the neurological and tissue immunoreactivity 
evaluations were analyzed using a homogeneity 
of variance test, followed by ANOVA of repeated 
measurement and one-way ANOVA tests, and a 
Tukey’s post hoc test to define differ-ences bet-
ween groups. We used the SPSS Statistics™ soft-
ware (20.0 version) and a p ≤0.05 significance. All 
experimental groups were processed in parallel 
for reducing variability. The data are presented as 
mean ± SEM.
Results
CDK5 reduction promoted neurological recovery 
in ischemic rats
The neurological assessment showed that the 
Isch-SCR animals had a lower score (12.8 and 
14.3 points) at days 7 and 15 post-ischemia, res-
pectively, compared with the sham groups with 
and without CDK5 RNAi treatment (16.5 points). 
Interestingly, the CDK5 RNAi-treated ischemic 
group presented a significantly higher score of 14.5 
on day 7 and of 16 points on day 15, recovering 
neurological skills similar to those of the control 
animals (figure 1C; p<0.05 = *, p<0.001 = **, 
repeated-measures in ANOVA).
BrdU incorporation in the hippocampus was 
promoted by CDK5 RNAi treatment in ischemic 
rats
We found a significantly increased number of 
BrdU+ cells in the Isch-SCR group compared 
with the sham-SCR and sham-CDK5 controls 
(figure 2A a; p<0.05 = *, p<0.001 = **, repeated-
measures in ANOVA and Tukey’s test). However, 
the CDK5 RNAi treatment induced a significantly 
greater incorporation of BrdU in ischemic animals 
compared with the Isch-SCR group without 
treatment (figure 2A a). Although there was no 
significant incorporation of BrdU in the polymor-
phic area of the Isch-SCR animals compared to 
controls (figure 2A b; p<0.05 = *, p<0.001 = **, 
repeated-measures in ANOVA and Tukey’s test), 
CDK5 silencing significantly increased BrdU+ cells 
compared to Isch-SCR and controls in the cerebral 
zone (figure 2A b). This effect of CDK5 RNAi on 
ischemic rats remained for a month in the granular/
subgranular and polymorphic zones (figure 2 B b). 
The Isch-group had a slight tendency or signifi-
cantly increased BrdU+ cells in comparison with the 
control groups (figure 2B a, b).
CDK5 RNAi exerted neuroprotection associated 
with the induction of immature neurons and 
down-regulation of the astroglial population in 
ischemic rats
Our findings showed that CDK5 RNAi treatment 
induced proliferation of immature neurons in the 
granular/subgranular zones. This is supported by 
the significant increase of BrdU+ and DCX+ cells 
in comparison with ischemic and control groups at 
15 days post-ischemia (figure 3A, C; p<0.05 = *, 
p<0.001 = **, repeated-measures in ANOVA and 
Tukey’s test). Although the sham-CDK5 and Isch-
SCR groups presented a significant increase of 
BrdU in the granular/subgranular zones, this was 
not confirmed by the variations in the amount of 
DCX+ or GFAP+ cells (figure 3A, C). On the other 
side, the polymorphic zone presented variability 
between groups and treatments (figure 3B, c; p 
< 0.05 = *, p<0.001 = **, repeated-measures in 
ANOVA and Tukey’s test), however, there was a 
significant increase of BrdU+ and GFAP+ cells in 
the ischemic-SCR group 15 days post-ischemia, 
which was significantly down-regulated by the 
CDK5 RNAi treatment in ischemic rats (figure 3B, 
C). The green fluorescent protein (GFP) was used 
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to confirm the expression of AAV2.5.shSCRmiR.
GFP and AAV2.5.shCDK5miR.GFP in each group, 
respectively.
CDK5 RNAi preserved the down-regulation of 
astrogliosis at one month post-ischemia
Interestingly, when we evaluated the neural popu-
lation at 30 days post-ischemia, we did not find 
changes in the mature neuron immunoreactivity 
neither in the granular/subgranular nor in the 
polymorphic zones in the untreated and treated 
rats, because there was a significant increase 
in the BrdU+ cells but without changes in the 
NeuN immunoreactivity (figure 4A, B; p<0.05 = 
*, p<0.001 = **, repeated measures in ANOVA 
and Tukey’s test). The GFAP+ population did not 
present changes in the granular/subgranular zone 
either (figure 4A, B), but stayed increased in the 
polymorphic zone at one-month post-ischemia in 
untreated rats, which was reversed by the CDK5 
RNAi treatment as in the control groups (figure 4A, 
C, p<0.05 = *, p<0.001 = **, repeated measures in 
ANOVA and Tukey’s test). 
Discussion
Our data suggest that CDK5 RNAi exerts part of 
its neuroprotection effect by controlling immature 
neuron proliferation and reducing astroglial cells, 
which reflects in the recovery of the neurological 
function after an ischemic stroke.
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Figure 2. BrdU incorporation in the hippocampus of CDK5 RNAi-treated ischemic rats. A) Representative images at bregma -2.56 
mm of BrdU immunoreactivity in the granular-subgranular (a) and polymorphic (b) zones at 15 days and B) 28 days post-ischemia in 
treated and untreated rats. The error bars indicate the SEM. n= 5, p<0.05 = *; p<0.001 = **. All data are presented as mean ± SEM. 
10X. Scale bar=100 μm.
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CDK5 is an effective form of protection against 
an ischemic event (7), preventing the excitotoxic 
spreading of glutamate by the reduction of calpain 
and CDK5 activation (12,20). 
Complementarily, the present study suggests that 
the silencing of CDK5 in the hippocampus has 
positive consequences on the behaviour associated 
with the motor cortex (M1 and M2) and the sensory 
area (S1) (21-24) as the exploratory behaviour 
integrate the interaction of those areas in the 
spatial activity performed by the hippocampus (24-
26), whisker movement through the motor cortex by 
M1 stimulation, which strongly innervates reticular 
nuclei containing cholinergic premotor neurons of 
the vibrissae and, in parallel, the sensory cortex S1, 
which innervates the trigeminal interpolar nuclei of 
brainstem and plays a role in the retraction of the 
whiskers and, in turn, in the sensitivity of the paretic 
side of the animals (25,26). 
In addition, our recent observations support the 
influence of hippocampal CDK5 down-regulation 
on the neurological tasks and the performance of 
learning and memory functions, where the CDK5 
RNAi avoids cell death on cingulate cortex and 
thalamus at one and four months post-ischemia 
(unpublished data); these cerebral areas are in-
volved in motivation and motor control behaviours 
(27,28). Its mode of action also involves the BDNF/
TRKB pathway and the restoration of long-term 
potentiation (LTP) dysfunction after stroke in the 
hippocampus at one-month post-ischemia (12,18).
On the other hand, BrdU has been widely used 
for labelling new-born cells and proliferation of 
different cell types. It has been shown that in cere-
bral ischemia the inclusion of BrdU is a marker of 
proliferation or neurogenesis in brain niches (29), 
which was confirmed in our observations. It is 
well known that CDK5 plays an important role in 
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Figure 3. CDK5 RNAi induced immature neurons and down-regulation of astroglial population in ischemic rats. A) BrdU and DCX 
immunoreactivities in the granular-subgranular and polymorphic zones at 15 days post-ischemia in treated and untreated rats (A, C). 
BrdU and GFAP in the granular-subgranular and polymorphic zones (B, C) at 15 days post-ischemia in treated and untreated rats. 
The error bars indicate the SEM. n=5, p<0.05 = *; p<0.001 = **. All data are presented as mean ± SEM. Representative images at 
bregma -2.56 mm. 10X. Scale bar = 100 μm. 
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post-mitotic neurons, where its inhibition prevents 
immature neuron migration and progression to 
a mature stage in physiological conditions (30). 
But the cellular and molecular fate depend on the 
contexts and homeostatic balance between normal 
and pathological conditions (12,18). 
In our findings, CDK5 silencing in ischemia in-
creased the BrdU/DCX+ cells, maybe because its 
reduction could regulate the re-entry in the cell 
cycle for a correct balance between Cdk6 and 
Cdk4 and the E2F1/CDK5 nuclear complex (31-
36), or by the prevention of stem cell differentiation 
as CDK5 activity promotes neural differentiation 
through phosphorylation of the p27 protein in its 
187-threonine residue (37). Moreover, CDK5 may 
phosphorylate to DCX, an immature neurons 
marker, in the 297-serine residue during migration 
(38). Therefore, our data would suggest that CDK5 
RNAi induces DCX in an early stage, but it does not 
facilitate its migration and maturation since NeuN 
labelling was unmodified.
It has also been described that CDK5 RNAi induces 
the production of BDNF (14,18), a neurotrophic 
factor highly involved in neurogenesis, neuronal 
plasticity, and protection preventing proinflamma-
tory response (39,40). The neuroprotective action 
of CDK5 RNAi increased activation of a typical 
plasticity pathway, the BDNF/ERK/CREB, and its 
action is dependent on the TRKB receptor activity 
(18,39,40,41). Also, ERK signalling has been widely 
described as a mediator of neuronal plasticity and 
survival in physiological and neurodegenerative 
contexts (41).
Those sequential cascades of CDK5 RNAi-induced 
survival and plasticity events could also be associa-
ted with the control of astrocytes reactivity. GFAP 
is a marker of astrogliosis on brain disease, and its 
proliferation is related to the adverse progression 
of brain impairment, pro-inflammatory response, 
lymphocytic infiltration, cytokines release, and 
neurovascular uncoupling (1,3,6). Interestingly, 
CDK5 knock-down could prevent the astrogliosis 
Figure 4. CDK5 RNAi prevents astrogliosis at one-month post-ischemia. A) NeuN, BrdU and GFAP immunoreactivities in the 
granular-subgranular (A, B) and polymorphic (A, C) zones at 30 days post-ischemia in treated and untreated rats. The error bars 
indicate the SEM. All data are presented as mean+/-SEM. Representative images at bregma -2.56 mm. n=5, p<0.05 = *; p<0.001 = 
**. 10X. Scale bar = 100 μm
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in the short and long time post-injury, thus sup-
porting the potential translation of CDK5 RNAi-
based therapy (7,12,18,42,43). 
On the other hand, when CDK5 levels are 
decreased in astroglial cells, BDNF is released 
from those cells protecting neurons (42) and endo-
thelial cells in co-cultures (unpublished data), and 
recovering motor and neurological functions in 
ischemic rats (43). 
Moreover, our data suggest that CDK5 RNAi 
induces proliferation of other types of cells besides 
neurons, which were not detected by our current 
approach. However, in agreement with our pre-
vious studies we have found that silencing of CDK5 
induces an increase of endothelial cell marker 
PECAM1(43) and the adhesion cell protein p120ctn 
in the membrane of endothelial cells (unpublished 
data), suggesting that endothelial cells may be the 
other potential cell population involved in the CDK5 
RNAi-induced neuroprotection. This is supported 
by the recovery of the neurovascular unit as we 
have suggested previously (6), and is reflected in 
the physiological recovery of the neurological per-
formance (14,18,42,43).
In conclusion, our data suggest CDK5 reduction 
induces proliferation of immature neurons and 
blocks astrogliosis in the long-term after ischemic 
injury improving neurological function, which, toge-
ther with previous scientific evidence, supports the 
potential translation of CDK5 RNAi-based gene 
therapy in acute and chronic neurodegeneration.
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